MARCOS
GONZÁLEZ DÍAZ
Investigador en el periodo 1993-2023
Centre Hospitalier Regional et Universitaire de Lille
Lila, FranciaPublicaciones en colaboración con investigadores/as de Centre Hospitalier Regional et Universitaire de Lille (1)
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477